Product Description
Calcium folinate is a tetrahydrofolic acid. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Calcium-folinate)
Mechanisms of Action: TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Netherlands, Norway, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 51
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Adenocarcinoma|Biliary Tract Cancer|Colic|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Oncology Solid Tumor Unspecified|Pancreatic Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 2: Liver Cancer|Neuroendocrine Carcinoma|Pancreatic Ductal Carcinoma|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2025-520471-29-00 |
FCO-FOX-2024-01 | P3 |
Not yet recruiting |
Adenocarcinoma|Colic|Colorectal Cancer |
2030-12-31 |
|||
NCT05253651 |
MOUNTAINEER-03 | P3 |
Recruiting |
Colorectal Cancer |
2026-04-03 |
42% |
2025-02-22 |
|
NCT03020030 |
NCT03020030 | P3 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-11-30 |
40% |
2025-01-04 |
|
2024-510977-27-00 |
D7986C00001 | P2 |
Recruiting |
Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer |
2026-03-31 |
2025-05-02 |
Treatments |
|
NCT04469556 |
PASS-01 | P2 |
Completed |
Pancreatic Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma |
2025-03-05 |
2026-02-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03837977 |
NET02 | P2 |
Completed |
Neuroendocrine Carcinoma |
2024-11-26 |
57% |
2025-01-03 |
|
2018-000708-40 |
ARION | P2 |
Active, not recruiting |
Squamous Cell Carcinoma|Esophageal Cancer|Adenocarcinoma |
2024-06-05 |
2022-03-13 |
Treatments |
|
ACTRN12617001268336 |
SYS-CAPLIOX | P2 |
Recruiting |
Colorectal Cancer|Liver Cancer |
2023-05-01 |
2026-03-07 |
Treatments |
|
NCT07437287 |
CROCOBIL | P3 |
Not yet recruiting |
Biliary Tract Cancer |
2030-04-01 |
30% |
2026-02-28 |
Primary Endpoints|Treatments |
NCT06279130 |
NEOASIS | P3 |
Recruiting |
Oncology Solid Tumor Unspecified |
2029-01-29 |
17% |
2026-03-07 |
Primary Endpoints |
2022-501181-22-01 |
STEREOPAC-001 | P2 |
Recruiting |
Pancreatic Cancer|Adenocarcinoma |
2032-10-01 |
2025-05-02 |
Treatments |
|
NCT06792695 |
CANTOR | P2 |
Recruiting |
Colorectal Cancer |
2027-05-31 |
12% |
2025-10-08 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT07257575 |
SPACE-neo | P2 |
Active, not recruiting |
Gastrointestinal Cancer |
2027-01-31 |
12% |
2025-12-03 |
Primary Endpoints|Treatments |
NCT06107413 |
M24-311 | P2 |
Active, not recruiting |
Colorectal Cancer |
2026-12-01 |
12% |
2025-12-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03803553 |
NCT03803553 | P3 |
Recruiting |
Colorectal Cancer |
2026-12-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
2023-509814-12-00 |
2023-509814-12-00 | P2 |
Recruiting |
Colorectal Cancer |
2031-03-31 |
2025-05-02 |
||
2024-513008-32-00 |
M24-977 | P2 |
Not yet recruiting |
Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer |
2030-11-03 |
2025-05-02 |
Treatments |
|
NCT06628310 |
AndroMETa-GEA | P2 |
Recruiting |
Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer |
2030-10-01 |
12% |
2024-12-19 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
2020-003134-20 |
MEND-IT | P2 |
Active, not recruiting |
Colorectal Cancer |
2030-05-17 |
2022-03-13 |
Treatments |
|
NCT06205485 |
NEO-RT | P3 |
Recruiting |
Colorectal Cancer |
2030-01-30 |
2024-08-14 |
Primary Endpoints|Start Date |
|
2020-002141-42 |
PelvEx II | P3 |
Active, not recruiting |
Colorectal Cancer |
2028-07-03 |
2022-03-13 |
Treatments |
|
NCT07290985 |
AACR-ADOPT-GEA | P2 |
Not yet recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2028-06-01 |
12% |
2025-12-19 |
Primary Endpoints|Treatments |
2024-518469-84-00 |
ââD798VC00001â | P2 |
Not yet recruiting |
Colorectal Cancer |
2028-01-20 |
|||
2024-518841-12-00 |
NeoART | P2 |
Recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2027-12-31 |
12% |
2025-05-02 |
Treatments |
NCT06835387 |
HCRN GI23-617 | P2 |
Recruiting |
Adenocarcinoma |
2027-08-01 |
12% |
2025-04-04 |
Primary Endpoints|Start Date|Treatments|Trial Status |